The Safety and Effectiveness of 935U83 in HIV-Infected Patients
NCT00002338
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Raluridine
Sponsor
Glaxo Wellcome